Navigation Links
Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
Date:12/7/2008

TOKYO and EDISON, N.J., Dec. 7 /PRNewswire-FirstCall/ -- Daiichi Sankyo Company, Limited (TSE: 4568), announced today that it has initiated its pivotal Phase III trial for DU-176b, an investigational oral Factor Xa inhibitor, in patients with atrial fibrillation. DU-176b is being developed solely by Daiichi Sankyo.

The Phase III global study, Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation (ENGAGE-AF TIMI 48), will compare DU-176b with warfarin in preventing stroke and systemic embolic events (SEE) in patients with atrial fibrillation. The primary safety assessment will be the incidence of bleeding.

Results from a recently presented Phase II safety study showed that the incidence of major and clinically relevant non-major bleeding events reported in the once-daily DU-176b treatment groups (30 mg or 60 mg) was similar to that in the warfarin-treated patient group. The incidence of major and clinically relevant non-major bleeding events was significantly higher in the twice-daily DU-176b treatment groups (30 mg or 60 mg), compared to the warfarin group. The Phase III study will therefore randomize approximately 16,500 patients to one of three treatment groups: 30 mg DU-176b once daily, 60 mg DU-176b once daily, or warfarin. Those randomized to warfarin will be dosed once daily with dose adjustments to maintain International Normalized Ratio (INR) between 2.0 and 3.0.

This is an event-driven, Phase III, multinational, randomized, double-blind study with sites in North and South America, Africa, Asia, Europe, Australia and New Zealand. The expected median treatment duration of the study is 24 months; Daiichi Sankyo expects the study to conclude in the first half of 2012.

"There is a need for a safe and effective option for the prevention of clotting or stroke in patients with atrial fibrillation other than the current standard of care, warfarin, which
'/>"/>

SOURCE Daiichi Sankyo Company, Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
2. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
3. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
4. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
5. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
6. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
7. Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease
8. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
9. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
10. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
11. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015  Landauer, Inc. (NYSE: LDR ), ... and monitoring, outsourced medical physics services and high quality ... results for the fiscal second quarter 2015 after the ... The Company will also host a conference call ... p.m. Central Time (5:00 p.m. Eastern Time). Investors may ...
(Date:5/4/2015)... 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ... development and commercialization of innovative therapies for the ... a regulatory update on Zalviso and reported financial ... 2015. Zalviso Regulatory UpdateOn April 21, ... of Anesthesia, Analgesia, and Addiction Products (DAAAP or ...
(Date:5/4/2015)... 4, 2015  Fox Three Partners, LLC ("Fox ... lower middle market, announced today the acquisition of ... and based in Newport News, Virginia ... radiation products for medical professionals as well as ... Capital Partners ("Peninsula"), an investment company specializing in ...
Breaking Medicine Technology:Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Second Quarter 2015 Results And Conference Call 2AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 2AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 3AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 4AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 5AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 6AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 7AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 8Fox Three Partners, LLC Acquires Burlington Medical Supplies, Inc. 2
... 3, 2011 Hologic, Inc. (Hologic or the Company) ... and supplier of premium diagnostics products, medical imaging systems ... of women, today announced that it has appointed Christiana ... Ms. Stamoulis will serve on the Company,s Corporate Development ...
... advances have had a profound effect on how organizations ... evolving communication environment, companies need to continuously adjust their ... challenging, however, to gauge the effectiveness of all the ... internal and external communication options. In ...
Cached Medicine Technology:Hologic Announces Appointment of New Director 2Internal and External Communication Insights: Effective Approaches for Reaching Clients and Co-Workers 2
(Date:5/5/2015)... May 05, 2015 With the advent of ... enjoying the feel of warm breezes on bare skin. And ... on how to look their best in shorts, tank tops ... more people are turning to laser treatments for permanent hair ... Simply Posh Aesthetic Spa . “They're all veterans of ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 “We currently have larger ... states Marta Phillips, owner of SunGrubbies.com. “We felt it was ... to find a fashionable sun hat in an extra large size ... event.” , Fashionable derby sun hats such as the ... brim are now available in an extra large size , ...
(Date:5/5/2015)... San Francisco, Calif. (PRWEB) May 05, 2015 ... available online but these have focused primarily on personal ... the National Directory of Insurance (NDOI.com) has ... licensed insurance agents in the U.S. to present their ... public marketplace. , The result is significant and two-fold. ...
(Date:5/5/2015)... No one cares about health problems until they ... Prevention cite multiple sources causing poor indoor air quality ... quality (pollution) can bother your eyes, nose, and throat. It ... cancer.” , Toxic chemicals often get into the human body. ... or in some cases, absorb them through our skin. This ...
(Date:5/4/2015)... Visiopharm, the leader in image analysis for diagnostic ... round of financing with NorthCap Partners . The ... Visiopharm to further accelerate business growth and strengthen their ... diagnostic digital pathology solutions. , "It has been exciting ... solution has energized the pathologists, and how fast we ...
Breaking Medicine News(10 mins):Health News:Laser Hair Removal: Tips for Summertime Grooming 2Health News:Laser Hair Removal: Tips for Summertime Grooming 3Health News:SunGrubbies.com, a Leading Online Retailer of Sun Protection Products, Launches Their New Extra Large Size Fashion Sun Hats Collection 2Health News:NDOI Launch Brings Commercial Insurance Online for the First Time 2Health News:NDOI Launch Brings Commercial Insurance Online for the First Time 3Health News:revitaRUGS is Offering Area Rug Cleaning Discounts in Support of Asthma and Allergy Awareness Month This May 2Health News:revitaRUGS is Offering Area Rug Cleaning Discounts in Support of Asthma and Allergy Awareness Month This May 3Health News:Visiopharm Closes Investment Round to Grow Diagnostic Digital Pathology Business 2Health News:Visiopharm Closes Investment Round to Grow Diagnostic Digital Pathology Business 3
... with Patient Outcome in Neuroblastoma , Expression of ... patients whose tumors lacked CHD5 expression were more likely ... patients whose tumors expressed CHD5. , Neuroblastoma tumors often ... arm of chromosome 1, called 1p36.31. Garrett Brodeur, M.D., ...
... compromised blood, oxygen supply, study suggests , , TUESDAY, June ... name Namenda) may help reduce a form of brain ... Children,s Hospital Boston study. , Hypoxic-ischemia, a compromise ... to cerebral palsy and cognitive/behavioral problems. , In experiments ...
... VIEW, Calif., June 24 MAP,Pharmaceuticals, Inc. ... Telesso,Technologies Limited, formerly Eiffel Technologies Limited ("Eiffel"), ... Pharmaceuticals previously licensed,intellectual property and know-how, as ... to its supercritical fluid technology ("SCF")., ...
... Lack of Provisions for African American,Dialysis Patients, ... Tubbs Jones released this statement regarding the ... 2008. This legislation,prevents the pending 10 percent ... preventive and mental health benefits, improves,and extends ...
... Access To Community,Pharmacies, ALEXANDRIA, Va., June 24 ... 59 in favor of H.R. 6331, which represents ... critical,provisions for community pharmacies that speed up the ... to Medicaid generic,prescription drug reimbursement that would have ...
... LOS ANGELES, June 24 Sport Chalet, Inc.,(Nasdaq: ... opening of its new,50,500 sq. ft. store located at ... now has 52 Sport Chalet locations., A grand ... 27th,through Sunday, June 29th. Activities will include celebrity appearances,sports ...
Cached Medicine News:Health News:Also in the June 24 JNCI 2Health News:Also in the June 24 JNCI 3Health News:Also in the June 24 JNCI 4Health News:Also in the June 24 JNCI 5Health News:Alzheimer's Drug May Reduce Preemie Brain Injury 2Health News:MAP Pharmaceuticals Acquires Proprietary Drug Particle Formulation Technology From Eiffel/Telesso Technologies Limited 2Health News:MAP Pharmaceuticals Acquires Proprietary Drug Particle Formulation Technology From Eiffel/Telesso Technologies Limited 3Health News:Tubbs Jones Supports Medicare Improvements Bill 2Health News:Sport Chalet Opens Store in West Los Angeles 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 9.0 mm and length 8 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 19.0 mm and length 21 mm....
The Vitek 2 is a fully automated bacteriology system that performs bacterial identification and susceptibility testing analysis using a standard inoculum. It detects resistance and helps combat bacte...
IDS Rapid STR, a microbial identification system....
Medicine Products: